- Home
- DXR vs MDCX Comparison
DXR vs MDCX Comparison
Compare DXR & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DXR | MDCX |
|---|---|---|
| Founded | 1970 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.1M | 53.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | DXR | MDCX |
|---|---|---|
| Price | $14.25 | $1.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $25.00 | $23.50 |
| AVG Volume (30 Days) | 3.5K | ★ 317.8K |
| Earning Date | 02-27-2026 | 02-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.46 | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $66,306.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $37.92 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.55 | $1.45 |
| 52 Week High | $14.76 | $8.94 |
Technical Indicators
Market Signals| Indicator | DXR | MDCX |
|---|---|---|
| Relative Strength Index (RSI) | 58.72 | 38.88 |
| Support Level | $13.20 | $1.45 |
| Resistance Level | $14.76 | $1.70 |
| Average True Range (ATR) | 0.59 | 0.13 |
| MACD | 0.10 | 0.01 |
| Stochastic Oscillator | 86.45 | 25.00 |
Price Performance
Historical ComparisonAbout DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
About MDCX Medicus Pharma Ltd.
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.